Missouri Attorney General Catherine Hanaway has issued a formal cease-and-desist letter to pharmaceutical giant Eli Lilly, signaling a significant escalation in the ongoing legal and regulatory tug-of-war surrounding the federal 340B Drug Pricing Program. In a correspondence dated October 26, 2026, Hanaway demanded that the company immediately cease its policy of conditioning discounted drug access on the submission of private claims data by hospitals. This action positions Missouri as a key battleground in the national debate over whether manufacturers have the legal authority to impose unilateral requirements on the providers they serve under the 340B umbrella.
The 340B program, established by Congress in 1992, requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations—often referred to as "covered entities"—at significantly reduced prices. The intent of the legislation is to allow safety-net hospitals, clinics, and health systems to stretch scarce federal resources as far as possible, reaching more eligible patients and providing comprehensive services. For decades, the program operated with relatively limited friction, but in recent years, the relationship between pharmaceutical manufacturers and 340B providers has deteriorated into a series of litigious disputes regarding the scope of the program and the transparency of the supply chain.
The Core of the Dispute: Data vs. Discounts
At the heart of the current conflict is Eli Lilly’s mandate that hospitals provide detailed claims data as a prerequisite for receiving 340B pricing. Lilly and other manufacturers argue that this data is necessary to prevent "duplicate discounts," a scenario where a drug is subject to both a 340B discount and a Medicaid rebate. However, hospital systems, including the University of Missouri Health Care (UMHC), argue that the federal statute does not grant manufacturers the authority to impose such reporting requirements.
Attorney General Hanaway’s letter specifically highlights the case of UMHC, which operates seven hospitals across the state. Despite the health system reportedly complying with requests for claims data, Hanaway asserts that Lilly denied the requested discounts anyway. This, she argues, constitutes a violation of Missouri’s consumer protection and trade practice laws, alleging that the company has engaged in "false and misleading statements" by promising adherence to the 340B program while simultaneously erecting barriers that effectively preclude hospitals from accessing those benefits.
A Chronology of Escalating Tensions
The friction between Eli Lilly and the 340B community is not a sudden development but the culmination of years of policy shifting.
- 1992: Congress enacts the Veterans Health Care Act, establishing the 340B program to help safety-net hospitals manage rising drug costs.
- 2020–2021: Major pharmaceutical manufacturers, including Eli Lilly, begin notifying the Health Resources and Services Administration (HRSA) of plans to restrict 340B pricing for drugs dispensed through contract pharmacies, citing a lack of transparency.
- 2022–2024: Various legal challenges move through federal courts, with mixed rulings regarding the extent to which manufacturers can restrict distribution channels for 340B entities.
- 2025: Industry analysts note an uptick in state-level legislative and executive actions as federal regulatory guidance is perceived as insufficient to curb manufacturer-imposed restrictions.
- October 2026: Missouri Attorney General Catherine Hanaway intervenes, setting a November 26, 2026, deadline for Eli Lilly to rescind its claims data policy within the state.
Economic Impact and Program Sustainability
The financial stakes of this conflict are substantial. For many hospitals, the 340B program is not merely a subsidy but a foundational component of their operational budget. According to data from the American Hospital Association (AHA), 340B savings enable hospitals to provide uncompensated care, specialized pediatric services, and oncology treatments in rural and underserved areas that might otherwise be financially untenable.
Opponents of the current manufacturer restrictions argue that these policies effectively "tax" the healthcare system by shifting the administrative burden of data collection onto hospitals that are already operating on thin margins. Conversely, the pharmaceutical industry maintains that the program has expanded well beyond its original scope, particularly regarding the use of contract pharmacies, and that data sharing is a necessary evolution to ensure the integrity of the rebate process.
Legal and Regulatory Implications
The Missouri Attorney General’s intervention is significant because it shifts the venue of the conflict from federal administrative law to state consumer protection statutes. By framing the dispute as a matter of "false and misleading statements," Hanaway is invoking state-level authority to protect healthcare providers from what she characterizes as predatory business practices.
If this strategy succeeds, it could set a precedent for other state attorneys general to follow. If multiple states begin to enforce similar consumer protection mandates, the pharmaceutical industry may find itself facing a fragmented regulatory landscape, potentially forcing a shift in how national drug pricing policies are implemented. Legal experts observe that this maneuver places the burden on the manufacturer to prove that their data requirements are consistent with the federal 340B statute—a threshold that has been notoriously difficult to define in federal court.
Institutional Responses and Industry Outlook
While Eli Lilly has not yet issued a comprehensive public response to the Missouri Attorney General’s letter, the company has historically defended its data-reporting requirements as essential for "program integrity." In past public filings, the company has stated that it remains committed to the 340B program’s original intent but asserts that the modern supply chain requires enhanced visibility to prevent systemic abuse.
Healthcare systems, represented by groups like the 340B Health organization, have lauded the Missouri Attorney General’s action. Representatives from these groups argue that the "unilateral" nature of the manufacturer policies bypasses federal oversight and punishes the very institutions the 340B program was designed to protect. As the November 26 deadline approaches, the industry is bracing for potential legal action. If Eli Lilly maintains its policy, the Missouri Attorney General’s office will likely be forced to initiate litigation, which could lead to a landmark decision on the reach of state power over federal drug pricing mandates.
Analysis: The Path Forward
The situation in Missouri underscores a broader, systemic failure to reach a consensus on the modernization of the 340B program. The federal government’s inability to provide clear, enforceable guidelines that satisfy both the pharmaceutical sector’s desire for data integrity and the hospital sector’s need for administrative simplicity has created a vacuum. This vacuum is now being filled by state-level executive action.
The primary risk for both sides is the uncertainty of litigation. For manufacturers, a court ruling against them could invalidate their current strategies for controlling 340B pricing nationwide. For hospitals, a ruling in favor of the manufacturer could solidify the status quo, permanently increasing the administrative costs associated with accessing 340B discounts.
As the deadline for the cease-and-desist order looms, the pharmaceutical industry is watching closely. The Missouri case will likely serve as a litmus test for the viability of using state consumer protection laws to challenge federal-program-related policies. Whether this results in a compromise, a protracted legal battle, or a shift in federal legislative oversight remains to be seen, but the pressure on Eli Lilly and other manufacturers to justify their data-reporting requirements has never been greater. For now, the healthcare community remains in a state of suspended animation, waiting to see if the November 26 deadline will lead to a policy reversal or the opening of a new, highly contentious chapter in American healthcare litigation.
